Sublethal heat treatment promotes breast cancer metastasis and its molecular mechanism revealed by quantitative proteomic analysis

Xia, Shujun; Li, Xiaoyü; Xu, Shumao; Ni, Xiaofeng; Zhan, Weiwei; Zhou, Wei

doi:10.18632/aging.203884

Cited by 3 publications

(2 citation statements)

References 27 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Knockdown of BCLAF1 greatly reduced PD-L1 expression by promoting PD-L1 ubiquitination. Previously, using a similar method, a study focused on the expression profile of dysregulated proteins in sublethally heattreated breast cancer cells [25] . The overall expression of BCLAF1 was inhibited and the proliferation and invasion ability of breast cancer cells were activated in the sublethal heat-treated group.…”

Section: Resultsmentioning

confidence: 99%

Differential Gene Expression Analysis for Aromatase Inhibitors Treatment on Breast Cancer Patients

Li¹,

Yang²,

Liu³

2023

IJPS

View full text Add to dashboard Cite

Breast cancer is the most common global malignancy and the leading cause of cancer deaths for women. Aromatase inhibitors are clinically recommended therapy for the disorders. However, resistance to aromatase inhibitors therapies still occurs and the underlined molecular mechanisms are still poorly understood. The tumour specimens consisted of aromatase inhibitor-sensitive and aromatase inhibitor-resistant breast cancer patients, who were compared and the differentially expressed genes for aromatase inhibitor-sensitive patients were generated and related genetic network was explored. The enriched cellular process and signaling cassettes for aromatase inhibitor-sensitive patients were also in-depth investigated. Compared with the aromatase inhibitor-resistant patients, 896 genes showed a significant differential expression. 621 were significantly up-regulated and 275 were remarkably downregulated. From the interaction network, the differentially expressed genes including signal recognition particle 72, B-cell lymphoma-2 associated transcription factor 1, cathelicidin antimicrobial peptide and defensin alpha 1B could be considered as the key target genes for aromatase inhibitors treatment in breast cancer patients. These differentially expressed genes were enriched in processes involving immunoglobulin complex, cell division and others while, drug metabolism and other signalling mechanisms were enriched in aromatase inhibitors treatment of breast cancer patients. The study speculated several novel gene targets for aromatase inhibitors therapeutic treatment of breast cancer patients and initiated a beneficial direction for future aromatase inhibitors drug resistance research.

show abstract

Section: Resultsmentioning

confidence: 99%

Differential Gene Expression Analysis for Aromatase Inhibitors Treatment on Breast Cancer Patients

Li¹,

Yang²,

Liu³

2023

IJPS

View full text Add to dashboard Cite

show abstract

“… 21 CRIP1 also affects the interactions of tumor cells with components of the immune system in patients with breast cancer 21 , 22 and is considered as a new biomarker for osteosarcoma, prostate cancer and breast cancer. 23 CRIP1 also acts as a clinical prognostic factor in patients with acute myeloid leukaemia (AML) with t 8 , 21 translocation. 24 …”

Section: Introductionmentioning

confidence: 99%